To appraise the clinical and cost effectiveness of liposomal cytarabine and daunorubicin within its marketing authorisation for untreated, high risk, acute myeloid leukaemia.
Status Proposed
Process STA
ID number 1225

Project Team

Project lead Samantha Shannon

Email enquiries


Key events during the development of the guidance:

Date Update
18 August 2017 - 18 September 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance